
Astria Therapeutics (ATXS) Stock Forecast & Price Target
Astria Therapeutics (ATXS) Analyst Ratings
Bulls say
Astria Therapeutics Inc. demonstrates a positive outlook due to the favorable tolerance profile of its product candidates, particularly STAR-0310, which shows no adverse events related to antibody-dependent cellular cytotoxicity, indicating potential for improved efficacy over existing treatments. Additionally, the anticipated synergies from a merger with BioCryst are projected to enhance operational profitability from the first full year of revenue, thereby enriching Astria's financial performance and market position. The large commercial opportunity coupled with expected strategic growth initiatives positions Astria favorably for stakeholders, supported by a robust pipeline and significant news flow ahead.
Bears say
The financial outlook for Astria Therapeutics Inc is tempered by concerns regarding the potential for failed or inconclusive clinical trials that could hinder the development of its key product candidates, STAR-0215 and STAR-0310. Additionally, the company's ability to secure adequate funding is critical for progressing these drugs through the development pathway, and any shortfall in this area could significantly impact its financial stability. The risks associated with not meeting clinical milestones and the uncertain valuation, particularly in the context of potential acquisitions and competition, contribute to a cautious view on the company's stock performance.
This aggregate rating is based on analysts' research of Astria Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Astria Therapeutics (ATXS) Analyst Forecast & Price Prediction
Start investing in Astria Therapeutics (ATXS)
Order type
Buy in
Order amount
Est. shares
0 shares